Moderna stock plummets after vaccine trial data leak
Statements (6)
- Bearish
Moderna's stock price dropped after preliminary data on its skin cancer vaccine failed to meet high investor expectations.
- Bearish
Moderna shares fell 17% after leaked trial data showed promising results for its cancer vaccine treatment.
- Bearish
Moderna stock price sank after vaccine data leak
- Bearish
Moderna shares fell more than 25% on the news of cancer vaccine data.
- Bearish
Moderna, a pharmaceutical company, lost nearly 25% of its stock price on Wall Street following a leak on social media.
- Bearish
Moderna's stock price plummeted following the release of cancer-vaccine study data on social media.